Antibody Formulation
OwnerJoachim Momm, Hans-Joachim Wallnyinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel pharmaceutical formulations, in particular novel pharmaceutical formulations in which the active ingredient comprises human antibodies to human interleukin 1 beta (IL-1β), in particular ACZ885 antibody, pharmaceutical formulations which are stable and aggregate-free upon storage and delivery.
Claims15
1-14. (canceled)
A pharmaceutical formulation, comprising
- a) an antibody to IL-1β which comprises amino acids 20 to 118 of SEQ ID NO:1 and amino acids 20 to 107 of SEQ ID NO:2, and
- b) a buffer system selected from the group consisting of a citrate, histidine, sodium succinate, sodium phosphate and potassium phosphate buffer system,
- wherein the formulation has a pH from 5.5 to 7.5.
A pharmaceutical formulation, comprising 10 to 150 mg/ml of an antibody to IL-1β which comprises amino acids 20 to 118 of SEQ ID NO:1 and amino acids 20 to 107 of SEQ ID NO:2, 270 mM sucrose, 30 mM histidine and 0.06% polysorbate 80, wherein the pH of the formulation is 6.5.
A pharmaceutical formulation, comprising 10 to 150 mg/ml of an antibody to IL-1β which comprises amino acids 20 to 118 of SEQ ID NO:1 and amino acids 20 to 107 of SEQ ID NO:2, 270 mM mannitol, 20 mM histidine and 0.04% polysorbate 80, wherein the pH of the formulation is 6.5.
Dependencies are inferred from the claim text.